The Korean Journal of Nuclear Medicine (대한핵의학회지)

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Stability of $^{188}Re$ Labeled Antibody for Radioimmunotherapy and the Effect of Stabilizing Agents

방사면역치료용 $^{188}Re$ 표지 항체의 안정성과 안정제의 효과

  • Chang, Young-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Kim, Bo-Kwang (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Jeong, Jae-Min (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Chung, June-Key (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Lee, Seung-Jin (College of Pharmacy, Ewha Woman University) ;
  • Lee, Dong-Soo (Department of Nuclear Medicine, Seoul National University College of Medicine) ;
  • Lee, Myung-Chul (Department of Nuclear Medicine, Seoul National University College of Medicine)
  • 장영수 (서울대학교 의과대학 핵의학교실) ;
  • 김보광 (서울대학교 의과대학 핵의학교실) ;
  • 정재민 (서울대학교 의과대학 핵의학교실) ;
  • 정준기 (서울대학교 의과대학 핵의학교실) ;
  • 이승진 (이화여자대학교 약학대학) ;
  • 이동수 (서울대학교 의과대학 핵의학교실) ;
  • 이명철 (서울대학교 의과대학 핵의학교실)
  • Published : 2002.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: For clinical application of beta-emitter labeled antibody, high specific activity is imporiant. Carrier-free $^{188}Re$ from $^{188}W/^{188}Re$ generator is an ideal radionuclide for this purpose. However, low stability of $^{188}Re$ labeled antibody, especially in high specific activity, due to radiolytic decomposition by high energy (2.1 MeV) beta ray was problem. We studied the stability of $^{188}Re$ labeled antibody, and stabilizing effect of several stabilizers. Materials and Methods: Pre-reduced monoclonal antibody (CEA79.4) was labeled with $^{188}Re$ by incubating with generator-eluted $^{188}Re-perrhenate$ in the presence of stannous tartrate for 2 hr at room temperature. Radiochemical purity of each preparation was determined by chromatography. Human serum albumin was added to the labeled antibodies (2%). Stability of $^{188}Re-CEA79.4$ was investigated in the presence of ascorbic acid, ethanol, of Tween 80 as stabilizing agents. Results: Labeling efficiencies were $88{\pm}4%\;(n=12)$. Specific activities of $1.25{\sim}4.77MBq/{\mu}g$ were obtained. If stored after purging with $N_2$, all the preparations were stable for 10 hr. However, stability decreased in the presence of air. Perrhenate and $^{188}Re-tartrate$ was major impurity in declined preparation. colloid-formation was not a significant problem in all cases. Addition of ascorbic acid stabilized the labeled antibodies either under $N_2$ or under air by reducing the formation of perrhenate. Conclusion: High specific activity $^{188}Re$ labeled antibody is unstable, especially, in the presence of oxygen. Addition of ascorbic acid increased the stability.

목적: 베타입자 방출 핵종을 표지한 항체를 임상적으로 이용하기 위해서는 높은 비방사능을 가지는 것이 중요하다. $^{188}W/^{188}Re$ 발생기를 사용하여 쉽게 얻을 수 있는 무담체 $^{188}Re$은 이런 목적에 이상적인 방사성 핵종이다. 하지만 높은 비방사능의 $^{188}Re$이 표지된 항체는 높은 베타 에너지(2.1 MeV)로 인한 불안정성이 문제가 된다. 우리는 $^{188}Re$이 표지된 항체의 안정성을 확보하기 위해 몇 가지 안정제가 미치는 영향에 대해서 조사하였다. 대상 및 방법: 환원시킨 단일클론항체(CEA79.4)에 stannous tartrate와 발생기에서 용출한 $^{188}Re-perrhenate$를 넣어 실온에서 2시간 반응시켰다. 각각의 방사화학적순도는 크로마토그라피를 써서 확인하였다. 표지된 항체에 사람 혈청 알부민(HSA)을 첨가(최종농도 2%)하고 ascorbic acid, ethanol, Tween 80 존재 하에서의 안정성을 각각 조사하였다. 결과: 표지된 항체의 비방사능은 $1.25{\sim}4.77MBq/{\mu}g$, 표지 효율은 $88{\pm}4%\;(n=12)$였다. 안정제로 ascorbic acid, ethanol, Tween 80을 첨가하였을 때 $N_2$ 존재 하에서 모든 경우에 10시간까지 안정하였으나, 공기와 접촉 시 10시간 후에 방사화학적순도는 각각 처음의 100, 45, 36%가 되었다. 과산화레늄(perrhenate)과 $^{188}Re-tartrate$의 증가가 주된 요인이었으며 콜로이드 형성은 모든 경우에 큰 영향을 끼치지 않았다. Ascorbic acid 첨가는 공기 중에서 perrhenate의 형성을 줄임으로서 항체의 안정성에 가장 많이 기여하였다. 결론: 높은 비방사능의 $^{188}Re$이 표지된 항체는 공기 중에 노출되었을 때 불안정하였으며, ascorbic acid 첨가시 안정성을 향상시킬 수 있었다.

Keywords

References

  1. Eckelman WC, Paik CH, Reba RC. Radiolabelingof antibodies. Cancer Res 1980;40:3036-42.
  2. Griffiths GL, Goldenberg DM, Diril H, HansenHJ. Technetium-99m, rhenium-186, and rhenium188direct-labeled antibodies. Cancer 1994;73:761-8.
  3. Wilder RB, DeNardo GL, DeNardo SJ.Radioimmunotherapy: recent results and futuredirections. J cu« Oneal 1996;14: 1383-400.
  4. Chung JK, Yeo J, Lee DS, Park S, Lee MC,Kim BK, et al. Bone marrow scintigraphy usingtechnetium-99m-antigranulocyte antibody in hematologicdisorders. J Nucl Med 1996;37:978-82.
  5. Higuchi T, Inoue T, Sarwar M, Oriuchi N,Karasawa M, Naruse T, et al. Tc-99m- labelledchimeric human/mouse antigranulocyte antibodybone marrow scintigraphy: a preliminary clincalstudy. Nucl Med Comm 1998;19:463-74.
  6. Mausner LF, Srivastava SC. Selection ofradionuclides for radioimmunotherapy. Med Phys1993;20:503-9.
  7. John E, Thakur TJ, DeFulvio J, McDevitt MR,Damjanov 1. Rhenium-186-1abeled monoclonalantibodies for radioimmunotherapy: preparationand evaluation. J Nucl Med 1993;34:260-7.
  8. Rhodes BA, Lambert CR, Marek MJ Knapp FF,Harvey EB. Re-188 labelled antibodies. ApplRadiat Isot 1996;47:7-14.
  9. Iznaga-Escobar N. Re-188 direct labeling ofmonoclonal antibodies for radioimmunotherapyof solid tumors: biodistribution, normal organdosimetry, and toxicology. Nucl Med Bioi1998;25:441-7.
  10. Lee J, Lee DS, Kim YJ, Chang YS, Jeong JM,Shin SA, et al. Labeling and biodistribution ofRe-188-DTPA. Korean J Nucl Med 1997;31:42732.
  11. Kim YJ, Jeong JM, Chang YS, Lee DS, ChungJK, Lee MC, et al. Study of Re-188(V)-DMSAfor treatment of cancer: radiolabeling andbiodistribution. Korean J Nucl Med 1998;32:81-8.
  12. Kim YJ, Jeong JM, Chang YS, Lee YJ, Lee DS,Chung JK, et al. Preparation and biodistributionof Re-188 sulfur colloid. Korean J Nucl Med1998;32:298-304.
  13. Chang YS, Jeong JM, Lee DS, Chung JK, LeeMC. Quality control of tungsten-188/rhenium188generator. Korean J Nucl Med 1998;32:42532.
  14. Chang YS, Jeong JM, Kim BK, Cho JR, LeeDS, Chung J-K, et al. Effect of carrier onlabeling and biodistribution of Re-188-hydroxyethylenediphosphonate. Korean J Nucl Med2000;34:344-52.
  15. Mather SJ, Ellison D. Reduction-mediatedtechnetium-99m labeling of monoclonalantibodies. J Nucl Med 1990;31:692-7.
  16. John E, Thakur ML, Wilder S, Alauddin MM,Epstein AL. Technetium-99m-labeled monoclonalantibodies: influence of technetium-99m bindingsites. J Nucl Med 1994;35:876-81.
  17. Griffiths GL, Goldenberg DM, Knapp FF,Callahan AP, Chang CH, Hansen HJ. Directradiolabeling of monoclonal antibodies withgenerator-produced rhenium-188 for radioimmunotherapy:labeling and animal biodistributionstudies. Cancer Res 1991;51:4594-602.
  18. Normando IE. Direct radiolabeling of monoclonalantibodies with rhenium-188 for radioimmunotherapyof solid tumors-a review of radiolabelingcharacteristics, quality control and in vitrostability studies. Appl Rad Isotope 2001;54:399-406.
  19. Hong MK, Jeong JM, Chung J-K, Choi SR,Kim CK, Lee YJ, et al. 99mTc labelling kitpreparation and characteristics of anti- NCA-95monoclonal antibody. Korean J Nucl Med1996;30:541-7.
  20. Hong MK, Jeong JM, Yeo JS, Kim KM, ChangYS, Lee YJ, et al. In vitro properties andbiodistribution of Tc-99m and Re-188 labeledmonoclonal antibody CEA 79.4. Korean J NuclMed 1998;32:516-24.
  21. Salako QA, O'Donnell RT, DeNardo SJ. Effectsof radiolysis on yttrium-90-labeled Lym-Iantibody preparations. J Nucl Med 1998;39:66770.
  22. Wahl RL, Wissing J, Rosario RD, Zasadny KR.Inhibition of autoradiolysis of radiolabeled. monoclonal antibodies by cryopreservation. JNucl Med 1990;31:84-9.
  23. Chakrabarti MC, Le N, Paik CH, De Graff WG,Carrasquillo JA. Prevention of radiolysis ofmonoclonal antibody during labeling. J NuclMed 1996;37:1384-8.
  24. Hnatowich DJ, Virzi F, Winnard P, Fogarasi M,Rusckowski M. Investigations of ascorbate fordirect labeling of antibodies with technetium99m.J Nucl Med 1994;35:127-34.
  25. Seymour CB, Mothersill C, Moriarty MJ, TiptonKF. The effect of ethanol on the radiationresponse of CHO-KI cells. Br J Raiol 1987;60(714):577-81.